Phase II Trial of Dual LAG-3–PD-1 Inhibition With Neoadjuvant Relatlimab + Nivolumab in Resectable Stage III Melanoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Neoadjuvant relatlimab plus nivolumab produced high rates of pCR and MPR in patients with resectable stage III melanoma with a tolerable safety profile.
Format: Microsoft PowerPoint (.ppt)
File Size: 457 KB
Released: June 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Related Content

Dr Michael Davies highlights key studies presented at the 2022 Society for Melanoma Research Annual Congress in this commentary from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Download slides on selected studies from the 2022 Society for Melanoma Research Annual Congress, as reported by Clinical Care Options (CCO)

Released: October 31, 2022

Downloadable clinical resource with practical guidance on preventative care plans for transgender patients, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: October 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings